For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Gi Innovation, Inc.

USPTO Granted Patents = 12

EPO Patents = 5

Forward Citations = 4

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Myung Ho Jang (8 out of 11 patents)

Young Jun Koh (5 out of 14 patents)

Su Youn Nam (4 out of 8 patents)

4. Myoung Ho Jang (4 out of 7 patents)

5. Zungyoon Yang (2 out of 4 patents)

6. Young-Gyu Cho (2 out of 6 patents)

7. Young Chul Sung (2 out of 25 patents)

8. Heonchang Lim (1 out of 1 patent)

9. Bo-Gie Yang (1 out of 1 patent)

10. Kyungwha Lee (1 out of 1 patent)

11. Dan Bee Ha (1 out of 1 patent)

12. Young Min Oh (1 out of 1 patent)

13. Soontak Kwon (0 patent)

14. Young Min Oh (0 patent)

12 patents: Sort by Forward Citations

1. 12692307 - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAIN (2026-07-28),

2. 12642764 - FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS (2026-06-02),

3. 12478675 - PHARMACEUTICAL COMPOSITION FOR ENHANCING RADIOTHERAPY COMPRISING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN (2025-11-25),

4. 12414984 - Fusion protein comprising anti-CD73 antibody and IL-2, and use thereof (2025-09-16),

5. 12410233 - Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same (2025-09-09),

6. 12409203 - Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising same (2025-09-09),

7. 12291555 - Fusion protein comprising IL-2 protein and CD80 protein, and use thereof (2025-05-06),

8. 12286464 - Fusion protein comprising IL-2 protein and CD80 protein, and use thereof (2025-04-29),

9. 12128076 - Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof (2024-10-29),

10. 11857601 - Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug (2024-01-02),

11. 11639383 - Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain (2023-05-02),

12. 11492384 - Fusion protein comprising IL-2 protein and CD80 protein, and use thereof (2022-11-08),

Company Overview

Gi Innovation, Inc. is a technology-driven company based in Seoul, South Korea, specializing in the development and manufacturing of advanced medical devices. The organization focuses on innovative solutions that enhance healthcare delivery and patient outcomes. With a commitment to research and development, Gi Innovation explores cutting-edge technologies in the medical field, aiming to address critical healthcare challenges and improve the quality of life for patients globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

12 Patents

#346 in Seoul

#936 in South Korea

#48,163 in the World

Seoul, South Korea

Gi Innovation, Inc.

Forward Citations = 4

11 inventors:

Myung Ho Jang (8 out of 11 patents)

Young Jun Koh (5 out of 14 patents)

Su Youn Nam (4 out of 8 patents)

4. Myoung Ho Jang (4 out of 7 patents)

5. Zungyoon Yang (2 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gi Innovation, Inc.. Retrieved from https://idiyas.com/company/gi-innovation

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…